Lilly files the Mounjaro KwikPen application with FDA

On September 28, 2023, Eli Lilly filed a supplement with the Food and Drug Administration, labeled NDA 215866/S-009, asking to add six new versions of the Mounjaro KwikPen ^[1]. Each of the six pens is meant for use by a single patient and is preloaded with four fixed weekly doses of tirzepatide, the active ingredient in Mounjaro ^[1]. The pens are designed for once-weekly injection, matching how tirzepatide is already dosed ^[1].

The path to approval was not straightforward. The FDA issued what is known as an action letter on January 29, 2025, and Lilly's own regulatory filing confirms this required a "complete response" — meaning the agency did not approve the pens as originally submitted and Lilly had to address FDA concerns before trying again ^[1]. Lilly submitted that complete response on December 2, 2025, more than two years after the original filing ^[1]. The FDA's formal approval letter is dated January 20, 2026, and the approval covers revised prescribing information, an updated Medication Guide, and new carton, container, and instructions-for-use materials specific to the KwikPen ^[1].

The approval letter also notes some regulatory housekeeping that will play out over the coming weeks. Because the KwikPen supplement did not introduce a new active ingredient, indication, dosage form, dosing regimen, or route of administration, Lilly is exempt from pediatric study requirements under the Pediatric Research Equity Act for this particular change ^[1]. The FDA also classified tirzepatide's KwikPen as a "Part 3 combination product," meaning Lilly must follow additional postmarketing safety reporting rules that apply to combination drug-device products ^[1].

Why it matters for patients

For people who already use Mounjaro, this approval means the drugmaker now has six additional single-patient-use KwikPen options available, each holding four weekly doses in one pen ^[1]. The exact dose volumes in each of the six presentations were redacted in the public version of the FDA letter, so the specific dose strengths tied to each new pen are not yet known from this document ^[1]. It is also not stated in the letter when these new pen options will actually reach pharmacies or how they might affect what patients see on pharmacy shelves or in mail-order shipments.

The more than two-year gap between filing and approval, including a full rejection cycle, is a reminder that even packaging and delivery-device changes for an already-approved drug can take significant time to clear FDA review. Patients relying on tirzepatide for their prescribed treatment were not affected by this particular delay in the sense that the existing Mounjaro products on the market continued to be available; this filing was specifically about adding new KwikPen presentations, not about the drug's approval status itself ^[1].

What happens next

Under the terms of the approval, Lilly has firm deadlines to finish the paperwork. The company must submit the official content of labeling in a standardized electronic format within 14 days of the January 20, 2026 approval letter ^[1]. Final printed carton and container labels for the new KwikPen presentations are due within 30 days of being printed ^[1]. Lilly must also submit required patent information to the FDA for the Orange Book listing within 30 days of approval ^[1]. None of the source material indicates a specific date when the six new KwikPen presentations will be available for patients to fill prescriptions.